Overall, these data suggest that combining Sl-IFN and CTX stimulates a local and systemic cellular immune response, whose principal actors are CD8+T cells and TIDC, leading to a prolonged reduction of tumor growth as compared to each single treatment alone. The gene discussed is CD8A; the disease is neoplasm.